Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 300 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 400 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: lactose; purified talc; maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

double-e pharma ltd. - racecadotril 100 mg - capsule, hard - 100 mg - racecadotril 100 mg - racecadotril

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dermal laboratories ltd - isopropyl myristate; liquid paraffin - cutaneous gel - 150mg/1gram ; 150mg/1gram

Israel - English - Ministry of Health

ofek pharma ltd, israel - posaconazole - tablets delayed release - posaconazole 100 mg - posaconazole - treatment of the following fungal infections in adults:- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b.- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patient intolerant to itraconazole.- coccidioidomycosis in patients with disease refractory to amphotericin b, itraconazole or fludonazole or in patient intolerant to these medicinal products.- zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.these are also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplatic syndrome (mds) expected to result in prolonged neutropenia who are at high-risk of developing invasive fungal infections.-hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high-risk of developing invasive fungal infections.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dermal laboratories ltd - isopropyl myristate; liquid paraffin - cutaneous gel - 150mg/1gram ; 150mg/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - guaifenesin, quantity: 20 mg/ml; bromhexine hydrochloride, quantity: 0.6 mg/ml - oral liquid - excipient ingredients: xanthan gum; peg-40 hydrogenated castor oil; citric acid; purified water; glycerol; potassium sorbate; saccharin sodium; ethyl maltol; propylene glycol; flavour - expectorant and mucolytic for the symptomatic relief of productive chesty coughs.

Australia - English - Department of Health (Therapeutic Goods Administration)

symbion pty ltd - amylmetacresol,dichlorobenzyl alcohol,sodium carbonate monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - guaifenesin, quantity: 20 mg/ml; bromhexine hydrochloride, quantity: 0.6 mg/ml - oral liquid - excipient ingredients: citric acid; purified water; ethyl maltol; potassium sorbate; peg-40 hydrogenated castor oil; xanthan gum; propylene glycol; glycerol; saccharin sodium; flavour - expectorant and mucolytic for the symptomatic relief of productive chesty coughs.